Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients

References

• Shankland W E. Medullary and odontogenic disease in the painful jaw: clinicopathologic review of 500 consecutive lesions. Cranio 2002; 20: 295–303
   PubMed Web of Science ®Google Scholar
• Black G V. A Work on Special Dental Pathology2nd edn. Medico-Dental Co., Chicago, IL 1915; 388–391
   Google Scholar
• Wilensky A O. Osteomyelitis of the jaw. Arch Surg 1932; 25: 215
   Google Scholar
• Hankey G T. Osteomyelitis (necrosis) of the jaws: its pathology and treatment. Br Dent J 1938; 63: 552
   Google Scholar
• Brotons A, Penarrocha M. Orofacial neurogenic pain and maxillofacial ischemic osteonecrosis. A review. Med Oral 2003; 8157–8165
   Google Scholar
• Bouquot J E, McMahon R E. Neuropathic pain in maxillofacial osteonecrosis. J Oral Maxillofac Surg 2000; 58: 1003–1020
   PubMed Web of Science ®Google Scholar
• Marx R E. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41: 283–288
   PubMed Web of Science ®Google Scholar
• Marx R E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115–1118
   PubMed Web of Science ®Google Scholar
• Wang J, Goodger N M, Pogrel M A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104–1107
   PubMed Web of Science ®Google Scholar
• Migliorati C A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253–4254
   PubMed Web of Science ®Google Scholar
• Ruggiero S L, Mehrotra B, Rosenberg T J, Engroff S L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527–534
   PubMed Web of Science ®Google Scholar
• Hellstein J W, Marek C L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 2005; 63: 682–689
   PubMed Web of Science ®Google Scholar
• Heiman H. Chronic phosphorus poisoning. J Indust Hyg 1946; 28: 142
   PubMedGoogle Scholar
• Pogrel M A. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004; 62: 391–392
   PubMed Web of Science ®Google Scholar
• Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004; 117: 440–441
   PubMed Web of Science ®Google Scholar
• Assael L A. New foundations in understanding osteonecrosis of the jaws (editorial). J Oral Maxillofac Surg 2004; 62: 125–126
   PubMed Web of Science ®Google Scholar
• Greenberg M S. Intravenous bisphosphonates and osteonecrosis (editorial). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 259–260
   PubMed Web of Science ®Google Scholar
• Migliorati C A, Schubert M M, Peterson D E, Seneda L M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. An emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83–93
   PubMed Web of Science ®Google Scholar
• Marx R E, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567–1575
   PubMed Web of Science ®Google Scholar
• Durie B GM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99–100
   PubMed Web of Science ®Google Scholar
• Woo S B, Hande K, Richardson P G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 100
   Google Scholar
• Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 100–101
   Google Scholar
• Carter G, Goss A N, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182: 413–415
   PubMed Web of Science ®Google Scholar
• Bagan J V, Murillo J, Jimenez Y, Hernandez S, Poveda R, Sanchis J M, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120–123
   PubMed Web of Science ®Google Scholar
• Vannucchi A M, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005; 128: 738
   PubMedGoogle Scholar
• Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32: 1123–1128
   PubMed Web of Science ®Google Scholar
• Lenz J H, Steiner-Krammer B, Schmidt W, Feitkau R, Mueller P C, Gundlach K KH. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Craniomaxillofac Surg 2005; 33: 395–403
   PubMed Web of Science ®Google Scholar
• Gibbs S DJ, O'Grady J, Seymour J F, Prince H M. Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust 2005; 183: 549–550
   PubMed Web of Science ®Google Scholar
• Sanna G, Zampino M G, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 2005; 16: 1207–1213
   PubMed Web of Science ®Google Scholar
• Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates (editorial). Joint Bone Spine 2006; 73: 7–9
   PubMed Web of Science ®Google Scholar
• Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945–952
   PubMed Web of Science ®Google Scholar
• Schwartz H C. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 2004; 62: 763
   PubMed Web of Science ®Google Scholar
• Bennett C L, Nebeker J R, Lyons E A, Samore M H, Feldman M D, McKoy J M, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA 2005; 293: 2131–2140
   PubMed Web of Science ®Google Scholar
• Ruggiero S, Gralow J, Marx R E, Hoff A O, Schubert M M, Huryn J M, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2: 7–14
   PubMedGoogle Scholar
• Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart J M, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055–1061
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538–6544
   PubMed Web of Science ®Google Scholar
• O'Connell M B, Elliot M E. Osteoporosis and osteomalacia. Pharmacotherapy: A Pathophysiologic Approach, T DiPiro. McGraw-Hill, New York, NY 2002; 1690
   Google Scholar
• Bamias A, Kastritis E, Bamia C, Moulopoulos L A, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580–8587
   PubMed Web of Science ®Google Scholar
• Chabner B A. Oncologist 2005; 10: 301–303, (editorial)
   Web of Science ®Google Scholar
• Cohen L. Further studies into the vascular architecture of the mandible. J Dent Res 1960; 39: 936–946
   PubMedGoogle Scholar
• Oikarinen V J. The inferior alveolar artery: a study based on gross anatomy and arteriography, supplemented by observations on age changes. Suom Hammaslaak Toim, Finska Tandlakarsallskapets Forhandlingar 1996; 61(Suppl 1)1–131
   Google Scholar
• Bradley J C. Age changes of the inferior alveolar artery. Br J Oral Maxillofac Surg 1988; 26: 517–519
   PubMed Web of Science ®Google Scholar
• McGregor A D, MacDonald D G. Age changes in the human inferior alveolar artery: a histological study. Br J Oral Maxillofac Surg 1989; 27: 371–374
   PubMed Web of Science ®Google Scholar
• Chow T W, Hellums J D, Thiagarajan P. Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation. J Lab Clin Med 2000; 135: 66–72
   PubMedGoogle Scholar